Navigation Links
Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
Date:3/3/2009

financings. www.safeguard.com

Forward Looking Statements

The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company's ability to continue to develop and expand its diagnostic services business, the Company's ability to expand and maintain a successful sales and marketing organization, the Company's ability to maintain compliance with financial and other covenants under the Company's credit facilities, limitations on the Company's ability to borrow funds under its credit facilities based on the Company's qualified accounts receivable and other liquidity factors, the Company's ability to obtain annual renewals of or replacements for its credit facilities, the effects of a going concern audit opinion on the Company's operations, the Company's ability to successfully transition its billing function in-house from a third party vendor, whether the conditions to payment of all or any portion of the contingent consideration from the Company's prior sale of its instrument systems business to Zeiss are satisfied, the Company's ability to remediate the material weaknesses in the Company's internal control over financial reporting, the continuation of favorable third party payer reimbursement for laboratory tests, the Company's ability to obtain additional financing on acceptable terms or at all, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
2. Clarient Reports First Quarter 2008
3. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
4. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
5. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
6. Clarient Generates 52% Revenue Increase in Third Quarter 2007
7. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
8. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
9. Clarient to Present at the UBS 2007 Global Life Sciences Conference
10. Diageo Chateau & Estate Wines Renews Official Wine Sponsorship of Elton John AIDS Foundation(R)
11. Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... new UCLA study has shown this is definitely the case ... how to treat their prostate cancer. , UCLA researchers found ... a much more difficult time making treatment decisions, called decisional ... their care and their long-term outcomes. , The study should ... the findings to target men less likely to know a ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 10 portions a week of tomatoes have an 18 ... research suggests. , With 35,000 new cases every year ... is the second most common cancer in men worldwide. ... experts believe is linked to a Westernised diet and ... recommendations reduces risk of prostate cancer, researchers at the ...
(Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 Bedros Keuilian ... franchise in the world, the leading fitness boot camp ... TV’s Gym Rescue reality series. One thing he knows very ... as a subject matter expert in the fitness business. , ... YouTube, he lays out a step-by-step instructional guide on how ...
Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... EP MedSystems,(Nasdaq: EPMD ) announces the following Webcast: What: ... 4:30 pm EST, Where: http://www.videonewswire.com/event.asp?id=43653 , How: ... web at the ... 856-753-8533, If ...
... in related literature. One extremely rare case was recently ... Journal of Gastroenterology because of its maximum diameter of ... clinical and histopathological findings, diagnostic methods and treatment by ... , The article reported one patient who presented to ...
... OCTOBER 25, 2007 Shire plc (LSE: ... biopharmaceutical company, announced that data from a 12-month ... Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA ... in children aged 6 to 12 years. ...
... formation of a cancer is proven to be a ... a definite carcinogen, the role of Helicobacter pylori (H ... unclear. An article to be published on November 7 ... mechanism explaining the promotional effect of H pylori on ...
... Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition") (NASDAQ: ... of US$7.5,million representing the second half of the ... agreement with a subsidiary of,Elan Corporation, plc ("Elan") ... drug,candidate ELND-005/AZD-103. ELND-005/AZD-103 has completed Phase I ...
... 500 health ... plans on quality of care, service, WASHINGTON, Oct. 26 ... Assurance (NCQA) today unveiled the third,edition of America,s Best Health ... plans. Coinciding with the,November launch of "open season," when many ...
Cached Medicine News:Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The largest colonic lipoma to date 2Health News:Long-term 12-month safety data on ADHD patch DAYTRANA 2Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
(Date:8/26/2014)... Aug. 26, 2014  Actavis plc (NYSE: ACT ... Brenton Saunders , CEO and President of Actavis, will ... the Morgan Stanley Global Healthcare Conference 2014 in ... The presentation will take place on ... the Grand Hyatt New York, 109 East 42 nd ...
(Date:8/26/2014)... , Aug. 26, 2014 Reportlinker.com ... is available in its catalogue: ... 2020 http://www.reportlinker.com/p02280977/Japan-Esophagoscopes--Gastroscopes-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s ... Outlook to 2020", provides key market data ...
(Date:8/26/2014)... Research and Markets  has announced the ... 2014-2018" report to their offering. Intranasal ... the administration of drugs for the treatment of local ... allergic and non-allergic rhinitis and sinusitis. The nose is ... vaccination and systematic drug delivery. Continuous ...
Breaking Medicine Technology:Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... 2011 , The deadly E. ... thousands across Europe has been sequenced using 454,Life Sciences, ... and detailed genetic analysis to date" of this,particularly virulent ... performed by scientists at the UK,s Health,Protection Agency and ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Number of PE/VC Investments in Small ... in the Past Four Years ...
Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 2Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 4Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 5Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 6Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 7Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 8Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 9Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 10Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 11
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
... is the unique combination laser system for ... of a button switch between SLT or ... Selecta Duet affords you the opportunity to ... the same setting with the benefits inherent ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Medicine Products: